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Assessing the merits of existing pancreatic cancer biomarkers
Paweł Kiczmer, Alicja Prawdzic Seńkowska, Błażej Szydło, Elżbieta Świętochowska,  
Zofia Ostrowska
Pancreatic ductal adenocarcinoma (PDAC) suffers from a very poor prognosis because early stages of the disease are 
asymptomatic and thus diagnosis is delayed until late. Discovering a suitable PDAC biomarker could thereby improve 
PDAC treatment by having an early diagnosis. The carbohydrate antigen, CA 19-9, currently used for diagnostics, 
may help in assessing the disease stage, however it is unsuitable for screening purposes. PDAC specific nucleotides 
can be detected in plasma but not at the early stages of the cancer. Furthermore, measuring circulating tumour cells 
(CTCs) in patient blood entails high costs and is only useful for advanced stage disease. Other potential PDAC marker 
candidates are Laminin g2A, Cyclophilin B and blood circulating adipokines, which seem to hold particular promise. 
At present, making early PDAC diagnosis is limited. The potential markers described herein might in the future be 
introduced into clinical practice however further studies are still required. Using combinations of several biomarkers 
also merit consideration, which may increase the overall sensitivity and specificity of PDAC detection. 
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) represents 
about 3% of all human malignant tumours [1]. It is one 
of those cancers occurring in highly developed countries, 
especially for men in their 70s and 80s. Over 20% cases 
are diagnosed when carcinogenesis is already at an ad-
vanced stage, including infiltration to adjacent organs or 
the presence of distant metastases. At the beginning of 
the disease, progression is asymptomatic whereas in late 
stage, the clinical picture becomes abruptly aggravated 
with symptoms depending on tumour localization, size 
and progression stage. When suspecting pancreatic can-
cer, ultrasonography is recommended, whose sensitivity is 
estimated to be at 80–90% [2]. Other medical tests applied 
are computed tomography and endoscopic retrograde cho-
langiopancreatography. Morbidity rates are very high; the 
five-year survival rate for radically treated patients being 
3–18% [2]. Radical surgery is possible in only 20% cases due 
to the advanced stage of cancer upon diagnosis [3, 4]. The 
ability for detecting this cancer early could thus considerably 
improve its prognosis. Discovering a new biological marker 
may thereby accelerate the diagnosis and enable the deli-
very of appropriate treatment at an early disease stage. The 
presented work attempts to evaluate the utility of several 
potential pancreatic cancer markers (Tab. I). 
CA 19-9, CA 125, CA 242, CEA
Carbohydrate antigens CA 19-9, CA 125 and CA 242 are 
often investigated and described, together with carcinoem-
bryonic antigen (CEA), so that specificity and sensitivity may 
be improved when these biomarkers are jointly measured. 
CA 19-9 is a sialylated Lewis (a) antigen which is absent in 
3–7% of the general population with a Lewis (a–b) blood-
type antigen [5]. 
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Amidst all the known PDAC markers, only CA 19-9 has been 
currently employed in diagnostics. Its sensitivity rate is 79% and 
specificity 82%, which limits its clinical value making it impos-
sible to distinguish pancreatic cancer from benign pancreatic 
diseases and multiple carcinoma [6]. Because CA 19-9 is not 
tumour-specific protein, serum concentrations may also be 
elevated in patients with inflammatory diseases of the digestive 
tract and liver disease; particularly cholelithiasis [7]. 
In the 1980s in Japan, an attempt to introduce CA 19-9 
for screening purposes was made [8]. A study on 70,940 
healthy individuals showed increased concentrations 
(> 37 U/ mL) of the marker in 1063 cases (1.5%). There was 
no evidence of cancer in patients having concentrations of 
37–100 U/mL whereas CA 19-9 levels were > 100 U/ mL in 
89 patients in whom 15 cancer cases (19%) were detected 
which included 4 instances of PDAC; two of these qualify-
ing for radical surgery. This study thereby concluded that 
CA 19-9 as a PDAC screening marker was unsuitable. Never-
theless, CA 19-9 is the marker of choice when monitoring 
patients with ductal carcinoma of the pancreas [7]. High 
postoperative CA 19-9 levels have been associated with 
poor survival and may identify those patients who, as an 
alternative, should receive systemic therapy [6]. Dong et 
al. reported that a preoperative serum CA 19-9 concentra-
tion > 338.45 IU/mL may be a prognostic factor for poor 
prognosis [9]. According to Hartwig et al., postoperative 
CA 19-9 decreases are associated with longer survival whe-
reas increased post-operative CA 19-9 might in addition 
be a prognostic factor for a poorer prognosis [3]. Some 
researchers suggest that postoperative CA 19-9 elevation 
is associated with a microscopic positive tumour margin 
and poorer survival as a consequence [10]. 
CA 19-9 could also be useful in monitoring the phar-
macotherapy of PDAC. Boone et al. observed that a > 50% 
decrease in CA 19-9 levels is correlated with a longer survival 
of patients who underwent neoadjuvant therapy [11]; Tzeng 
et al. obtained similar outcomes [12]. Further studies are 
needed to confirm whether failure to normalise CA 19-9 
levels could be an independent predictor of shorter survival. 
CA 125 or MUC16 belong to the mucin family of gly-
coproteins [13] and is mostly known for detecting ovarian 
cancer [14]. To date, it has not been suggested for PDAC 
screening, nonetheless it may play a complementary role in 
PDAC diagnosis and prognosis besides that of CA 19-9 [15]. 
Chinese Study Group for Pancreatic Cancer considered CA 
125 to be useful in the diagnosis and detection of metastasis, 
as well as in selecting the appropriate therapy and for mo-
nitoring disease progression, regression and recurrence [16, 
17]. Interestingly, according to Luo et al. CA 125 is superior to 
CA 19-9 for predicting the resectability of pancreatic cancer 
where high levels may indicate an unresectable pancreatic 
cancer [18]. 
CEA (carcino-embryonic antigen) is glycoprotein in-
volved in cell adhesion and has been used for diagnosing 
recurrent colorectal cancer [19] and it might also prove 
useful for detecting PDAC. As a single marker, CEA is of 
low sensitivity (30–88%) but when combined with others 
sensitivity may become increased [20]. 
CA 242 is also a tumour marker for sialylated Lewis car-
bohydrates that has been suggested for PDAC diagnosis. 
It appears to have the highest specificity when compa-
red to CA 19-9, CA 125 and CEA but has a low sensitivity 
(67.8%), however it may improve the CA 19-9 discrimination 
rate [21–23]. 
A valuable study by Yu-Lei et al. jointly measured serum 
levels of CA 19-9, CEA, CA 125 and CA 242 in PDAC patients 
and achieved a higher detectability of 90.4% sensitivity 
and 93.8% specificity, than when markers were measured 
alone [21]. 
Nucleotides
MiRNA molecules are small single stranded RNAs consi-
sting of 18–22 nucleotides, which modulate posttranscrip-
tional expression of several genes. MiRNA deregulation may 
not only be associated with upregulation of genes involved 
in cancer progression (cell proliferation, migration and in-
vasion), but also with apoptosis evasion, and chemoresi-
stance [24]. A study by Xu et al. suggested that miR-486-5p 
allows the discrimination of patients between PDAC, chronic 
pancreatitis and normal subjects (AUC = 0.861) [25]. The 
study demonstrated that miR-938 is comparable to CA 19-9 
when differentiating patients with PDAC from CP. 
Because the miRNA profile consists of a panel of up-
-regulated or down-regulated miRNAs responsible for 
many of the aforementioned aspects of tumorigenesis, 
then evaluating this profile may provide a more sensitive 
and more specific method than measuring a single miRNA. 
For instance, miR-16 and miR-196a together with CA19-9, 
constitute an effective set of first stage tumour markers. 
Indeed, some workers believe that miRNAs may have a role 
in assessing a  patient’s prognosis and their selection for 
treatment [26]. As an example, upon measuring circulating 
non-coding RNAs (ncRNAs) in cases of advanced PDAC, 
useful information can be gained, such as predicting the 
patient’s response to chemotherapy. Furthermore, Humeau 
et al. reported that PDAC-specific MiRNA can be detected in 
saliva samples [27] and indicate that MiR-23a and MiR-23b 
Table I. Clinical relevance of potential PDAC biomarkers
Potential screening markers Potential monitoring markers
Nucleotides
Adipokines
Laminin 2a
Cyclophilin B
CA 19-9
CA 125
CEA
CA 242
CTC
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are both present in patients with intraductal papillary mu-
cinous neoplasms; otherwise known as non-invasive PDAC 
precursors. Another suggested and promising PDAC biomar-
ker is circulating cell-free DNA (cfDNA). This arose from the 
conception of a ‘liquid biopsy’, which consist of analysing 
pieces of nucleic acids from tumour cells in collected blood 
sample [28, 29]. CfDNA is derived from somatic DNA released 
into the systemic circulation following cellular necrosis and 
apoptosis. Hadano et al. found that KRAS-mutated cfDNA 
was associated with significantly poorer survival in patients 
with resectable tumours [29] and it was suspected that the 
cfDNA tumour found may correlate with micrometastases, 
which are undetectable by imaging methods. This suggests 
that cfDNA-positive patients may be considered for any 
preoperative options such as neo-adjuvant chemotherapy. 
These outcomes have been confirmed by other studies [28, 
30, 31]. Kisiel et al. detected PDAC hypermetylated DNA in 
pancreatic juice [32] and reported that such PDAC specific 
DNA-methylation markers may discriminate between early 
disease stage from normal tissue. Matsubayashi et al. like-
wise detected hypermethylated PDAC cfDNA in pancreatic 
juice [33]. T In summary, both cfDNA and MiRNA should be 
therefore considered as potential PDAC screening markers. 
It is also worth mentioning that MiRNA can be isolated from 
the saliva, which is a non-invasive method allowing prema-
lignant pancreatic lesions to become detected. 
Circulating tumour cells (CTCs)
CTCs are tumour cells circulating in blood vessels with 
metastatic potential. They have been detected in patients 
suffering from breast, lung and prostate cancers [34]. Kule-
mann et al. found CTCs in 73% of PDAC patients (n = 11); 
with CTCs being found in patients at every stage of the 
disease [34]. Earl et al. measured CTCs in 20% of such cases 
(n = 35) [31] with six out of all seven patients with CTCs ha-
ving metastases; one patient had a resectable tumour. These 
outcomes lead us to conclude that CTC may be a sensitive 
PDAC biomarker. In addition, PDAC is poorly vascularised 
and its invasion is often limited to the liver, and only involves 
other organs at very advanced stages [31, 35, 36]. 
Bissolati et al. investigated CTCs in portal blood collec-
ted during PDAC surgery [35] and showed no differences 
in survival rate between CTC-positive and CTC-negative 
patients. An increased risk of liver metastasis was however 
found in CTC-positive patients. It should be noted that CTC 
isolation is very expensive and we believe that it cannot be 
used as a screening biomarker but may be applied when 
monitoring PDAC progression. 
Adipokines
Adiponcetin is a 244-aminoacids cell signalling peptide 
(cytokine) synthesised in adipocytes with serum concen-
trations being inversely proportional to the percentage of 
body fat [37]. Adiponectin plasma levels correlate inversely 
with cancer risk; especially those associated with obesity 
and insulin resistance. This cytokine has been suggested 
as a potent inhibitor of angiogenesis in vivo [38]. Other 
studies also indicate that, in vitro, it may inhibit endothelial 
cell migration and induce cell apoptosis via activation of 
caspases. Concentrations of plasma adiponectin is signifi-
cantly higher in PDAC patients (24.95 mg/mL) compared to 
healthy (10.4 mg/mL) patients and chronic pancreatitis cases 
(10.3 mg/mL) [37]; Chang et al. obtained similar results [39]. 
In contrast, Pezilli et al. observed no significant differences 
in adiponectin serum levels between controls and a PDAC 
group [40]. There is evidence that the adiponectin serum 
level is inversely proportional to PDAC risk [41]. Serum adi-
pokine levels increase during the course of PDAC. Based on 
the aforementioned studies, adiponectin may thus become 
a future PDAC biomarker.
Another described adipokine, leptin, is a 167 aminoacid 
protein where its serum concentrations are proportional to 
the body fat mass [37]. Leptin is supposed to be a marker 
differentiating autoimmune pancreatitis patients from those 
with chronic pancreatitis (CP) and pancreatic cancer where 
significantly lower serum levels were measured in patients 
with CP and PDAC compared to autoimmune pancreatitis [40]; 
without any significant differences between CP and PDAC [40]. 
Sakamoto et. al also observed no differences in serum leptin 
concentrations between PDAC and CP groups [42]. In summary, 
adiponectin may play a part as a PDAC biomarker, whereas 
leptin has low significance in the diagnosis of this cancer. 
Laminin
Laminins are high molecular weight glycoproteins con-
tributing to basement membrane structure. They are made 
up of three polypeptide chains: the a, b and g encoded 
collectively into 11 genetic variants [43]. The gamma chain 
emerges in three different genetic polymorphisms; one of 
which encodes subtype laminin gamma 2 (LAMC2) which 
has been suggested as a potential PDAC biomarker [44]. 
Kosanam et al. measured increased serum levels in PDAC 
patients (382.2 ng/mL) compared to those for benign tu-
mours (140 ng/mL) and healthy individuals (87 ng/mL). 
LamC2 (AUC = 0.87) outperforms CA19-9 (AUC = 0.82) in 
differentiating between healthy and cancer patients. In con-
trast, CA19-9 is superior upon comparing benign and PDAC 
patients. The combined use of LAMC2 and CA19.9 could 
thereby permit a more effective discrimination between 
age-matched normal and benign patients from PDAC pa-
tients than the single marker measurement of CA 19.9 [44]. 
Cyclophilin B
Cyclophilins are group of proteins acting as molecular 
chaperones that fold, translocate and process newly syn-
thesized proteins. Cyclophilin B (CypB) is a 21-kDa protein 
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belonging to the cyclophilin family of peptidyl-prolyl cis-
trans isomerases. By reversible modification of their protein 
structure, cyclophilins also serve as signalling switches, reg-
ulating the activities of transforming growth factor b recep-
tor, epidermal growth factor receptor, tyrosine kinases and 
transcription factors such as c-Myb and interferon regulatory 
factor 4 [45]. Cyclophilins are widely expressed in the human 
body and highly conserved throughout evolution. Increased 
expression of cyclophilin B was observed in stomach and 
breast cancers [46]. Ray et al. measured increased Cyp B 
serum levels in 24 patients with PDAC [47]. The mean CypB 
level was 295 ng/mL in the PDAC group and 60 ng/mL in 
the controls (n = 24). The authors believe that increased 
secretion of CypB into the bloodstream may be caused by 
oxidative stress in the hypoxic tumour environment. 
Conclusion
At present, there are no tests available for confirming 
PDAC that are easy-to-perform, specific, sensitive, non-in-
vasive and that are of prognostic value. Early detection and 
choosing appropriate treatment may significantly reduce 
mortality and increase survival time in patients suffering 
from pancreatic cancer. Although advanced methods such 
as computed tomography and ultrasonography are com-
monly used in medical practice, the mortality rate remains 
very high. The main reason is that diagnosis is made too late. 
Twenty percent cases are diagnosed at a very advanced sta-
ge and qualified only for surgical treatment. Thirty percent of 
such patients undergoing surgery are expected to relapse. 
The only appropriate marker available, CA 19-19, is however 
unsuitable for asymptomatic cases. At this time, hopes can 
be pinned on measuring adipokines as in the aforementio-
ned instance of adiponectin and MiRNA profiles should also 
be considered as useful PDAC biomarkers. Measuring CTCs 
however is expensive and labour-intensive and therefore 
inappropriate for clinical practice. It is thus our opinion 
that a combination of measuring several biomarkers might 
increase the sensitivity and specificity of detection and allow 
such means to be introduced for the screening of PDAC. 
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